Clinical Trial

Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential. This research aims to determine the long-term immune response after administration of one dose of Bio TCV and PQed TCV vaccines in the population in Indonesia. Research participants will be taken from research participants who complete the Bio TCV (Typhoid 0319) Phase III clinical trial research included in the Main Study Group I.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-08.
Trial Details
NCT Number NCT06921460
Lead Sponsor PT Bio Farma
Conditions Antibody Typhoid Vaccine
Enrollment 624 participants
Start Date 2025-06-15
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-03